SPA
MYGN icon

Sherbrooke Park Advisers’s Myriad Genetics MYGN Stock Holding History

Sherbrooke Park Advisers’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,172
Closed -$54K – 649
2025
Q2 		$54K Sell
10,172
-16,638
-62% -$98.3K 0.02% 496
2025
Q1 		$238K Buy
+26,810
New +$322K 0.11% 378
2024
Q4 		– Sell
-22,413
Closed -$614K – 1028
2024
Q3 		$614K Buy
+22,413
New +$607K 0.14% 234

Other funds holding MYGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Sherbrooke Park Advisers's MYGN Position: Q3 2025 in Review

Sherbrooke Park Advisers sold out of Myriad Genetics (MYGN) in Q3 2025, closing a stake of 10,172 shares — an estimated $54K sold.

Sherbrooke Park Advisers first reported a position in MYGN in Q3 2024 and held it in 3 quarters. The position peaked at $614K in Q3 2024. 221 funds tracked by Wall St. Rank hold MYGN as of Q3 2025.

  • Sherbrooke Park Advisers reported no remaining Myriad Genetics position as of Q3 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 10,172 Myriad Genetics shares in Q3 2025, an estimated $54K.
  • Sherbrooke Park Advisers first reported a position in Myriad Genetics in Q3 2024 and held it in 3 quarters.
  • Sherbrooke Park Advisers's Myriad Genetics position peaked at $614K in Q3 2024.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.